Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia.
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2013
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms PERTAIN
- Sponsors Janssen-Cilag
- 17 Jun 2009 Planned number of patients changed from 294 to 294 as reported by ClinicalTrials.gov.
- 17 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 17 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.